TABLE 1.
θ defensins used in this studya
| Number | Name | Comment | Sequence |
|---|---|---|---|
| 1 3 5 6 8 10 11 1315 1618 | |||
| RTD 1 | Net charge, +5 | GFCRC LCRRG VCRCI CTR | |
| RTD 2 | Net charge, +6 | GVCRC LCRRG VCRCI CRR | |
| RTD 3 | Net charge, +4 | GFCRC ICTRG FCRCI CTR | |
| RC 100 | Retrocyclin 1 | Net charge, +4 | GICRC ICGRG ICRCI CGR |
| RC 100b | Retrocyclin 2 | Net charge, +5 | GICRC ICGRR ICRCI CGR |
| RC 100c | Retrocyclin 3 | Net charge, +6 | RICRC ICGRR ICRCI CGR |
| RC 101 | K9-retrocyclin 1 | R→K | GICRC ICGKG ICRCI CGR |
| RC 102 | Y6-retrocyclin 1 | I→Y | GICRC YCGRG ICRCI CGR |
| RC 103 | Y15-retrocyclin 1 | I→Y | GICRC ICGRG ICRCY CGR |
| RC 104 | Y2-retrocyclin 1 | I→Y | GYCRC ICGRG ICRCI CGR |
| RC 105 | Y11-retrocyclin 1 | I→Y | GICRC ICGRG YCRCI CGR |
| RC 106 | Y4-retrocyclin 1 | R→Y | GICYC ICGRG ICRCI CGR |
| RC 107 | Y9-retrocyclin 1 | R→Y | GICIC ICGYG ICRCI CGR |
| RC 108 | Y13-retrocyclin 1 | R→Y | GICIC ICGRG ICYCI CGR |
| RC 110 | Retroenantio RC 100 | All D, 18→1 | RGCIC RCIGR GCICR CIG |
| RC 111 | Retro RC 100 | All L, 18→1 | RGCIC RCIGR GCICR CIG |
| RC 112 | Enantio RC 100 | All D, 1→18 | GICRC ICGRG ICRCI CGR |
| RC 113 | Enantio RC 101 | All D, 1→18 | GICRC ICGKG ICRCI CGR |
| RC 114 | K9, Y15-retrocyclin 1 | R→K, I→Y | GICRC ICGKG ICRCY CGR |
a
RC 109 (sequence not shown) was not made. Residues that differ from the corresponding residues of retrocyclin 1 (RC 100) are in boldface. Since the peptides were cyclic, the residue numbers are arbitrary. The residues in one nonapeptide domain of each RTD and retrocyclin are underlined.